Ventoux Biosciences
Modulating Fibrosis, Restoring Function
https://wefunder.com/ventoux.biosciences
Total raised on Wefunder: 0
Total investors: 0
Quick facts
- Founded by a Dupuytren's patient to transform care for millions with immune-fibrotic diseases
- Targeting Dupuytren's and Spinal Cord Injury with VEN-201, a novel, immune-fibrotic modulator
- VEN-201 rebalances the immune system to reduce fibrosis and activate repair
- 2025 Pre-Clinical Biopharmaceutical Company of the Year Winner, by GHP Biotechnology Awards
- $4.3B Dupuytren's disease market, >3x larger than Rheumatoid Arthritis - no approved treatments
- SCI: ~$10B annually, VEN-201 targets fibrosis, addressing the key market opportunity in recovery
- Strong IP: Broad immune-fibrotic patent to 2044, global filings plus key provisional filings